Parvinder Thiara
Directeur/Membre du Conseil chez ZURA BIO LIMITED
Fortune : 1 M $ au 30/04/2024
Profil
Parvinder Singh Thiara is the founder.
He founded Athanor Capital LP in 2017, where he holds the title of CIO & Chief Compliance Officer.
Currently, Mr. Thiara holds the position of Director at Tourmaline Sub, Inc. since 2022, Independent Director at Tourmaline Bio, Inc. since 2023, and Independent Director at Zura Bio Ltd.
since 2023.
In the past, he worked as a Senior Vice President at D.E.
Shaw & Co., Inc. Mr. Thiara has a graduate degree from the University of Oxford and an undergraduate degree from Harvard College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
0,32% | 25/10/2023 | 82 782 ( 0,32% ) | 1 M $ | 30/04/2024 |
Postes actifs de Parvinder Thiara
| Sociétés | Poste | Début |
|---|---|---|
| ZURA BIO LIMITED | Directeur/Membre du Conseil | 01/06/2023 |
Athanor Capital LP
 Athanor Capital LP Investment ManagersFinance Athanor Capital LP (Athanor) is a hedge fund manager headquartered in New York City. The firm was founded by Parvinder S. Thiara in 2017 and is a subsidiary of Athanor Capital GP LLC. Athanor serves as the investment adviser, with discretionary trading authority over private pooled investment vehicles. | Fondateur | 01/01/2017 |
Tourmaline Bio, Inc.
 Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Directeur/Membre du Conseil | 01/09/2022 |
Anciens postes connus de Parvinder Thiara
| Sociétés | Poste | Fin |
|---|---|---|
D.E. Shaw & Co., Inc.
 D.E. Shaw & Co., Inc. Investment ManagersFinance D.E. Shaw & Co., Inc. engages in the provision of investment advisory services. The firm offers services to pooled investment vehicles. The company was founded by David E. Shaw in 1988 and was headquartered in New York, NY. | Corporate Officer/Principal | - |
Formation de Parvinder Thiara
| Harvard College | Undergraduate Degree |
| University of Oxford | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ZURA BIO LIMITED | Health Technology |
| Entreprise privées | 3 |
|---|---|
Athanor Capital LP
Athanor Capital LP Investment ManagersFinance Athanor Capital LP (Athanor) is a hedge fund manager headquartered in New York City. The firm was founded by Parvinder S. Thiara in 2017 and is a subsidiary of Athanor Capital GP LLC. Athanor serves as the investment adviser, with discretionary trading authority over private pooled investment vehicles. | Finance |
Tourmaline Bio, Inc.
Tourmaline Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Tourmaline Bio, Inc., Tourmaline Sub, Inc. is a late-stage clinical biotechnology company based in New York, NY. The company's lead program, Tour006, is an anti-IL-6 antibody with high binding affinity and a naturally long half-life. Tour006 has been studied in over 400 autoimmune patients across six clinical trials. Tourmaline Sub plans to develop Tour006 for thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD), with additional indications being considered. The company, founded in 2021 by Sandeep Kulkarni and Caley M. Castelein, is focused on developing transformative medicines for patients with life-altering immune diseases. Sandeep Kulkarni has been the CEO since 2021. Tourmaline Sub was acquired by Talaris Therapeutics, Inc. on October 19, 2023, for $43.50 million. | Commercial Services |
D.E. Shaw & Co., Inc.
D.E. Shaw & Co., Inc. Investment ManagersFinance D.E. Shaw & Co., Inc. engages in the provision of investment advisory services. The firm offers services to pooled investment vehicles. The company was founded by David E. Shaw in 1988 and was headquartered in New York, NY. | Finance |